The factor Xa inhibitor rivaroxaban failed in reducing the risk of death, MI or stroke as compared with placebo among patients with worsening chronic heart failure (HF) and underlying coronary artery disease (CAD) without atrial fibrillation (AF), according to results of the COMMANDER HF trial reported at the European Society of Cardiology (ESC) Congress 2018.
Lorcaserin has become the first weight-loss agentto show cardiovascular (CV) safety in patients at high CV risk, according to results of the CAMELLIA–TIMI 61 study presented at the European Society of Cardiology (ESC) Congress 2018.
Drug-coated balloons (DCB) are noninferior to drug-eluting stents (DES) for the management of small native coronary artery disease (CAD), according to results of the BASKET-SMALL 2 trial presented at the European Society of Cardiology (ESC) Congress 2018.
Tafamidis, an oral disease-modifying agent used to delay the loss of peripheral nerve function in transthyretin amyloid polyneuropathy (ATTR-PN), is shown to improve survival and reduce hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTR-ACT trial.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.